Immunomodulation and preeclampsia

Marianna Pina Rambaldi, Eran Weiner, Federico Mecacci, Jacob Bar, Felice Petraglia*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Preeclampsia (PE) is an enigmatic syndrome, still with unknown aetiology and multi-factorial pathogenesis. Our understanding of the role of the immune system in PE development has undergone a transformation over the years. From a model based on the alterations in cell-mediated immunity, research moved on to a vision centred on the alteration of the humoural immunity and on the systemic involvement of the inflammatory system. The first hypothesis was classically derived from the evidence that an adequate maternal immunological response is necessary in pregnancy to allow the survival of the foetus. An abnormal response of the maternal immune system against the placenta may be the first pathogenetic step of PE, followed by a systemic inflammatory reaction. Currently available treatments for PE are mainly preventative with aspirin. Treatment aims to modulate inflammation and the immune system before their changes become established.

Original languageEnglish
Pages (from-to)87-96
Number of pages10
JournalBest Practice and Research in Clinical Obstetrics and Gynaecology
StatePublished - Oct 2019


  • Immune system
  • Inflammation
  • NK cell
  • PLGF
  • Preeclampsia
  • VEGF


Dive into the research topics of 'Immunomodulation and preeclampsia'. Together they form a unique fingerprint.

Cite this